[Phosphate binders for therapy of hyperphosphatemia causing secondary hyperparathyroidism and renal osteodystrophy in patients with chronic renal failure].
Kanagawa
S
S
Second Department of Internal Medicine, Saitama Medical School.
Yosikawa
Y
Y
Dohi
Y
Y
D000085:Acetates / Q000378:metabolism / Q000627:therapeutic use; D019342:Acetic Acid; D000481:Allantoin / Q000031:analogs & derivatives / Q000378:metabolism / Q000627:therapeutic use; D000536:Aluminum Hydroxide / Q000378:metabolism / Q000627:therapeutic use; D001639:Bicarbonates / Q000378:metabolism / Q000627:therapeutic use*; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy*; D002951:Citrates / Q000378:metabolism / Q000627:therapeutic use; D019343:Citric Acid; D004338:Drug Combinations; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications*; D008276:Magnesium Hydroxide / Q000378:metabolism / Q000627:therapeutic use; D010710:Phosphates / Q000097:blood* / Q000378:metabolism
D000085:Acetates; D001639:Bicarbonates; D002951:Citrates; D004338:Drug Combinations; D010710:Phosphates; D019343:Citric Acid; D000481:Allantoin; C013591:aluminum hydroxide, magnesium hydroxide, drug combination; D000536:Aluminum Hydroxide; C031556:calcium bicarbonate; C017231:aldioxa; D008276:Magnesium Hydroxide; D019342:Acetic Acid